GLPwatch

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice

NCT05443568 · Completed

Last updated 2026-05-28

This study is observing how the medication semaglutide, taken by mouth, affects blood sugar levels in adults with type 2 diabetes in Israel as part of their regular medical care.

Status Completed The study has finished.
Type Observational
Participants 155 people
Who can join Ages 18+ · all sexes
Timeline Started 2023-03 · est. completion 2024-11
Where 1 site · Israel

What this study is testing ClinicalTrials.gov NCT05443568 ↗

Description as written by the study sponsor.

The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.

Treatments tested

Main thing measuredChange in HbA1c (Glycated haemoglobin)
SponsorNovo Nordisk A/S
Conditions studiedDiabetes Mellitus, Type 2
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05443568 ↗